Industry Forecast: Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market to Generate $38.26 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?
The market size of programmed death (PD)-1 non-small cell lung cancer has seen substantial growth in the past and it’s projected to continue on this upward trajectory. Starting at $25.23 billion in 2024, the market is expected to expand to $27.50 billion in 2025, representing a compound annual growth rate (CAGR) of 9.0%. The historic growth can be linked to a number of factors including an increase in non-small cell lung cancer cases, the growing use of immunotherapy in developed countries, increased public awareness regarding cancer screening, more approvals being granted for monoclonal antibodies, and the continued increase in healthcare spending.
The market size for programmed death (PD)-1 non-small cell lung cancer is projected to grow robustly in the forthcoming years, reaching $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the projection period is linked to the escalating investments in cancer-dedicated infrastructure, the broadening of patient access to biological therapies in developing markets, the growth of the global aging population, the increasing financial backing for immunotherapies, and the rising success rates of clinical trials of PD-1 inhibitors. Expected trends during this same forecast period involve advancements in biomarker testing technology, improvements in combined immunotherapy protocols, funding in personalized treatment approaches, R&D for new PD-1 inhibitors, and innovative practices in immune checkpoint blockade mechanisms.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
#Which Factors Are Currently Driving The Growth Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
The escalation in the use of customized therapies is predicted to fuel the growth of the programmed death (PD)-1 non-small cell lung cancer market. Customized therapies are medical strategies specifically designed to match a person’s genetic makeup, lifestyle, and acute disease features to achieve superior targeted results. The swelling demand for these treatments comes in the wake of expanded access to genomic profiling and biomarker testing. These innovative methods help in the identification of specific mutations and biomarkers, enabling medical professionals to choose therapies that are more apt to be effective for each person. These tailored treatments aid programmed death (PD)-1 non-small cell lung cancer (NSCLC) by adjusting therapies based on a patient’s genetic makeup, tumor specifics, and immune reaction. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, declared that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a substantial increase from the 6 approved in 2022. Hence, the escalating use of personalized therapies is fueling the growth of the programmed death (PD)-1 non-small cell lung cancer sector.
How Is The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Structured In Terms Of Segments?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
What Upcoming Trends Are Expected To Impact The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Globally?
Leading organizations in the market for programmed death (PD)-1 non-small cell lung cancer are placing their efforts on executing clinical experiments of innovative treatments like monotherapy to enhance patient results. Monotherapy is a therapeutic approach that employs a single drug or treatment for a disease or condition. For example, Akeso, Inc., a biopharmaceutical firm based in China, revealed successful outcomes from its Phase III HARMONi-2 trial testing Ivonescimab (AK112) coupled with chemotherapy for the initial treatment of advanced non-small cell lung cancer (NSCLC) in March 2025. The trial reached its main objective by prominently extending progression-free survival compared to pembrolizumab, underscoring the therapeutic potential of the dual-targeted bispecific antibody.
Who Are The Main Participants Shaping The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Landscape?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.
Get The Full Report Here:
Which Region Currently Holds The Largest Share In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
